Trial Profile
Study to Compare Once-daily Extended Release Tacrolimus Versus Twice-daily Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce the Risk of Allosensitisation
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms EVITRA
- 27 Feb 2019 Planned End Date changed from 1 Oct 2023 to 1 Nov 2023.
- 27 Feb 2019 Planned primary completion date changed from 1 Oct 2021 to 1 Nov 2021.
- 27 Feb 2019 Status changed from not yet recruiting to recruiting.